FIVE PRIME THERAPEUTICS
FivePrime is discovering and developing novel therapeutic proteins and antibodies by systematically screening all relevant proteins in the human body to find the best protein for treatment of a given clinical indication. FivePrime’s ProScreen Engine enables the rapid production and screening of all therapeutically relevant proteins in medically-focused assays at the highest quality standards in the industry. ... This powerful approach is the polar opposite of the industry’s traditional “one protein at a time”. The ProScreen Engine comprises the definitive protein collection and screening process for biologics discovery and is unprecedented in its efficiency, quality, and scale. In addition to DBL Investors, investors include Domain Associates, Versant Ventures, Kleiner Perkins Caufield and Byers, Texas Pacific Group, HealthCap, and Advanced Technology Ventures.
FIVE PRIME THERAPEUTICS
Industry:
Biotechnology Health Care Medical Therapeutics
Founded:
2001-01-01
Address:
San Francisco, California, United States
Country:
United States
Website Url:
http://www.fiveprime.com
Total Employee:
101+
Status:
Closed
Contact:
415-365-5600
Email Addresses:
[email protected]
Total Funding:
155.04 M USD
Technology used in webpage:
SPF Microsoft Exchange Online Office 365 Mail IPv6 ReCAPTCHA Microsoft Azure DNS YouTube DoubleClick.Net ReCAPTCHA V2 Microsoft
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Kleiner Perkins
Kleiner Perkins investment in Private Equity Round - Five Prime Therapeutics
Versant Ventures
Versant Ventures investment in Private Equity Round - Five Prime Therapeutics
Pfizer Venture Investments
Pfizer Venture Investments investment in Venture Round - Five Prime Therapeutics
Kleiner Perkins
Kleiner Perkins investment in Venture Round - Five Prime Therapeutics
J.P. Morgan Securities Inc.
J.P. Morgan Securities Inc. investment in Venture Round - Five Prime Therapeutics
Domain Associates
Domain Associates investment in Venture Round - Five Prime Therapeutics
Diamond Capital Company
Diamond Capital Company investment in Venture Round - Five Prime Therapeutics
Wellcome Trust
Wellcome Trust investment in Venture Round - Five Prime Therapeutics
Singapore Bio-Innovations
Singapore Bio-Innovations investment in Venture Round - Five Prime Therapeutics
Advanced Technology Ventures
Advanced Technology Ventures investment in Venture Round - Five Prime Therapeutics
Official Site Inspections
http://www.fiveprime.com
- Host name: ewhserver1302.edgewebhosting.net
- IP address: 69.63.140.80
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Five Prime Therapeutics" on Search Engine
Amgen To Acquire Five Prime Therapeutics For $1.9 Billion in Cash
Mar 4, 2021 Amgen To Acquire Five Prime Therapeutics For $1.9 Billion in Cash. Acquisition Includes Bemarituzumab, A Phase 3 Ready, First-In-Class Program For Gastric Cancer, the Third Leading Cause of Cancer Mortality Worldwide. Bemarituzumab is a …See details»
Amgen Successfully Completes Acquisition Of Five Prime …
Apr 16, 2021 THOUSAND OAKS, Calif., April 16, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it has successfully completed its previously …See details»
Amgen Successfully Completes Acquisition Of Five Prime …
Apr 16, 2021 THOUSAND OAKS, Calif., April 16, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that it has successfully completed its previously announced …See details»
Five Prime Therapeutics - Crunchbase Company Profile & Funding
FivePrime is a clinical-stage biotechnology company that develops treatments for cancers. Acquired by. Amgen. San Francisco, California, United States. 101-250. Post-IPO …See details»
Amgen, with rare buyout, pays $1.9B for cancer biotech Five Prime
Published March 4, 2021. Ned Pagliarulo Lead Editor. Amgen Inc. Dive Brief: Amgen will buy cancer drugmaker Five Prime Therapeutics for $1.9 billion in a rare public …See details»
Prime time for Five Prime as Amgen snaps up this once …
Mar 4, 2021 After seeing the biotech's shares soar 300% late last year on positive new data for its midstage gastric cancer program, Amgen has stepped in with a $1.9 billion …See details»
Amgen completes $1.9B acquisition of Five Prime Therapeutics
Apr 16, 2021 Amgen (NSDQ:AMGN) announced today that it successfully completed its $1.9 billion acquisition of Five Prime Therapeutics (NSDQ:FPRX). Thousand Oaks, …See details»
Amgen Completes The Acquisition Of Five Prime …
April 20, 2021 — 11:28 am EDT. Written by Neha Gupta for TipRanks -> Amgen has completed the acquisition of the clinical-stage biotechnology company Five Prime Therapeutics. Amgen had...See details»
Amgen to Acquire Five Prime Therapeutics for $1.9B
Mar 4, 2021 Amgen to Acquire Five Prime Therapeutics for $1.9B. Mar 04, 2021 | staff reporter. Save for later. NEW YORK – Amgen said on Thursday it will acquire Five …See details»
Five Prime Therapeutics Agrees to Sell to Amgen for $1.9 Billion
San Francisco – March 16, 2021 – Cooley advised Five Prime Therapeutics, a publicly traded clinical-stage biotechnology company focused on developing immune modulators …See details»
Five Prime Therapeutics acquired by Amgen - Crunchbase
Mar 4, 2021 Five Prime Therapeutics FivePrime is a clinical-stage biotechnology company that develops treatments for cancers. Acquiring Organization: Amgen Amgen …See details»
Amgen To Acquire Five Prime Therapeutics For $1.9 Billion in Cash
Mar 4, 2021 Amgen To Acquire Five Prime Therapeutics For $1.9 Billion in Cash. Acquisition Includes Bemarituzumab, A Phase 3 Ready, First-In-Class Program For …See details»
Five Prime Therapeutics: Understanding Bemarituzumab
Dec 10, 2020 Five Prime Therapeutics is a clinical stage biotech company that is focused on development of novel protein therapies. Five Prime is based in San Francisco, …See details»
Phase 2 FIGHT Trial Results Presented at ASCO GI
Jan 15, 2021 SOUTH SAN FRANCISCO, Calif.-- ( BUSINESS WIRE )-- Five Prime Therapeutics, Inc. (NASDAQ: FPRX) today announced clinical results from the global, …See details»
Five Prime Celebrates Many Firsts in Positive Phase II
Nov 12, 2020 Five Prime Therapeutics Inc., in collaboration Zai Lab Limited on the development bemarituzumab, a novel therapy for front-line advanced non HER2+ gastric …See details»
Five Prime Therapeutics Company Profile - Craft
Overview. Five Prime Therapeutics is a biotechnology company focused on developing immuno-oncology and targeted cancer therapies.See details»
Five Prime Therapeutics Appoints Tom Civik as Chief Executive …
Apr 14, 2020 SOUTH SAN FRANCISCO, Calif.-- ( BUSINESS WIRE )-- Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused …See details»
Five Prime Therapeutics - Funding, Financials, Valuation
$345M. in funding over 9 rounds. Their latest funding was raised on Jan 1, 2018 from a Post-IPO Equity round. Five Prime Therapeutics is registered under the ticker …See details»
Five Prime Therapeutics Announces Collaboration with Roche to …
May 30, 2018 SOUTH SAN FRANCISCO, Calif.– ( BUSINESS WIRE )–Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on …See details»
Amgen to Acquire Five Prime Therapeutics for $1.9 Billion in Cash
Mar 4, 2021 Amgen to Acquire Five Prime Therapeutics for $1.9 Billion in Cash | Business Wire. Acquisition Includes Bemarituzumab, A Phase 3 Ready, First-In-Class …See details»